Analyst Price Target is $2.00
▲ +696.50% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Cardio Diagnostics in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 696.50% upside from the last price of $0.25.
Current Consensus is
Buy
The current consensus among 1 polled investment analysts is to buy stock in Cardio Diagnostics. This Buy consensus rating has held steady for over two years.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Read More